Injection Pen Market Size To Reach $76.4 Billion By 2033

June 2026 | Report Format: Electronic (PDF)

Injection Pen Market Growth & Trends

The global injection pen market size is expected to reach USD 76.4 billion by 2033, according to a new report by Grand View Research, Inc., registering a 7.7% from 2026 to 2033. High demand for these devices for management of various chronic as well as acute diseases and increasing awareness in developing regions are key factors expected to drive the market.

Injectable pens have witnessed significant success in improving patient convenience during management of chronic disease, a process that might include administering intermittent injections. These devices are more convenient and affordable than other delivery systems. Ongoing studies on the same to assess their applications in management of other diseases, including but not limited to Hepatitis C and cancer, is expected to ensure swift market growth through 2025.

Request a free sample copy or view report summary: Injection Pen Market Report

Injection Pen Market Report Highlights

The reusable segment dominated the market, accounting for 70.5% of the market share in 2025. This strong market growth is mainly driven by their long-term cost efficiency, reduced medical waste, and increasing adoption among patients requiring chronic disease management, particularly for diabetes, autoimmune disorders, and hormonal therapies.
Diabetes dominated the market, accounting for the largest revenue share in 2025. This growth is primarily driven by the rising prevalence of diabetes and the growing adoption of user-friendly, self-administered drug-delivery systems.
The hospital segment dominated the market in 2025, accounting for the largest revenue share, primarily due to the high volume of injectable treatments administered in hospital settings for chronic diseases, emergency care, endocrinology, oncology, and autoimmune disorders.
North America injection pen market accounted for the largest revenue share of 44.8% in 2025. The growth is supported by the rising prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis, which require frequent self-administration of injectable medications.